Liraglutide-induced oral hyperpigmentation: a case report and review of management strategies

Anhar K. Alzahrani; Mohammad A. Basendwh; Reema S. Alzaidi; Saleh M. Aldraibi; Amal H. Abualola

doi:10.18203/issn.2455-4529.IntJResDermatol20251050

Authors

Anhar K. Alzahrani Department of Dermatology, King Fahad Armed Hospital, Jeddah, Saudi Arabia
Mohammad A. Basendwh Department of Dermatology, King Fahad Armed Hospital, Jeddah, Saudi Arabia
Reema S. Alzaidi Department of Dermatology, King Fahad Armed Hospital, Jeddah, Saudi Arabia
Saleh M. Aldraibi College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia
Amal H. Abualola Department of Emergency, East Jeddah General Hospital, Jeddah, Saudi Arabia

DOI:

https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20251050

Keywords:

Oral hyperpigmentation, Asymptomatic hyperpigmentation, SPF

Abstract

A 41-year-old female patient with no significant past medical history presented with asymptomatic hyperpigmentation of the oral mucosal surfaces, noticed over two months. The onset of hyperpigmentation coincided with the use of Liraglutide injections for weight §mg. The patient was also taking ferrous sulfate supplements for the past two months without prior adverse effects. Physical examination revealed multiple hyperpigmented macules on the bilateral buccal mucosa, lower gingiva, lower alveolar mucosa, and anterior tongue, along with mild lip hyperpigmentation. Laboratory tests, including thyroid function and serology, were normal. Histopathological examination showed chronic interface mucositis. The patient was treated with topical tacrolimus 0.03% cream, applied once daily, resulting in significant improvement within one week. This case suggests a possible link between Liraglutide and oral hyperpigmentation, highlighting the importance of considering medication-induced etiologies in such presentations. Additionally, using lip balm with SPF is recommended to prevent further pigmentation.

Metrics

Metrics Loading ...

References

Rosebush MS, Briody AN, Cordell KG. Black and Brown: Non-neoplastic Pigmentation of the Oral Mucosa. Head Neck Pathol. 2019;13(1):47-55. DOI: https://doi.org/10.1007/s12105-018-0980-9

Binmadi NO, Bawazir M, Alhindi N. Medication-induced oral hyperpigmentation: a systematic review. Patient Prefer Adherence. 2020;14:1961-8. DOI: https://doi.org/10.2147/PPA.S275783

Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med. 2022;70(1):5-13. DOI: https://doi.org/10.1136/jim-2021-001952

Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019;10:155. DOI: https://doi.org/10.3389/fendo.2019.00155

Lee YH, Lee HW, Choi HJ. GLP-1 Based Combination Therapy for Obesity and Diabetes. J Obes Metab Syndr. 2017;26(3):155-60. DOI: https://doi.org/10.7570/jomes.2017.26.3.155

Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract. 2017;3(1):3-14. DOI: https://doi.org/10.1002/osp4.84

Boccardi A, Shubrook JH. Cutaneous reactions to antidiabetic agents: A narrative review. Diabetol. 2022;3(1):97-107. DOI: https://doi.org/10.3390/diabetology3010008

Chandra S, Keluskar V, Bagewadi A, Sah K. Extensive physiologic melanin pigmentation on the tongue: An unusual clinical presentation. Contemp Clin Dent. 2010;1(3):204-6.

Walia I, Kaushal N. Usual pigmentation at unusual sites: Series of 3 case reports. Usual pigmentation at unusual sites: Series of 3 case reports. Indian J Dent. 2014;5:116-8. DOI: https://doi.org/10.1016/j.ijd.2013.09.001

Chandra S, Keluskar V, Bagewadi A, Sah K. Extensive physiologic melanin pigmentation on the tongue: An unusual clinical presentation. Contemp Clin Dent. 2010;1(3):204-6. DOI: https://doi.org/10.4103/0976-237X.73205

Wawrzyńczak A. Cosmetic and pharmaceutic products with selected natural and synthetic substances for melasma treatment and methods of their analysis. Cosmetics. 2023;10(3):86. DOI: https://doi.org/10.3390/cosmetics10030086

Mallagray-Montero MC, Moreno-López LA, Cerero-Lapiedra R, Castro-Janeiro M, Madrigal-Martínez-Pereda C. Medication related to pigmentation of oral mucosa. Med Oral Patol Oral Cir Bucal. 2022;27(3):230-7. DOI: https://doi.org/10.4317/medoral.25110

El-Naggar NE, Saber WIA. Natural melanin: current trends, and future approaches, with especial reference to microbial source. Polymers (Basel). 2022;14(7):1339. DOI: https://doi.org/10.3390/polym14071339

Schlessinger DI, Anoruo MD, Schlessinger J. Biochemistry, Melanin. In: StatPearls. StatPearls Publishing. 2024. Available at: https://www.ncbi.nlm.nih. Accessed on 18 November 2024.

Ballard M, Shafiee A, Grage E, DeMarco M, Atala A, Ghadiri E. Inkjet printing of synthesized melanin nanoparticles as a biocompatible matrix for pharmacologic agents. Nanomaterials (Basel). 2020;10(9):1840. DOI: https://doi.org/10.3390/nano10091840

Brady MF, Rawla P. Acanthosis Nigricans. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2024. Available at: https://www.ncbi.nlm.nih.gov. Accessed on 28 December 2024.

Sisson EM. Liraglutide: clinical pharmacology and considerations for therapy. Pharmacother. 2011;31(9):896-911. DOI: https://doi.org/10.1592/phco.31.9.896

Jacobsen LV, Flint A, Olsen AK, Ingwersen SH. Liraglutide in type 2 diabetes mellitus: clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2016;55(6):657-72. DOI: https://doi.org/10.1007/s40262-015-0343-6

Dereure O. Drug-induced skin pigmentation. Epidemiology, diagnosis and treatment. Am J Clin Dermatol. 2001;2(4):253-62. DOI: https://doi.org/10.2165/00128071-200102040-00006

Balagula Y, Barth Huston K, Busam KJ, Lacouture ME, Chapman PB, Myskowski PL. Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). Invest New Drugs. 2011;29(5):1114-21. DOI: https://doi.org/10.1007/s10637-010-9567-3

Sukhdeo K, Yoon GH, Rothman L, Meehan SA, Levin MK, Kim RH. Mirtazapine-induced hyperpigmentation with type II histopathologic findings. JAAD Case Rep. 2018;4(10):1077-9. DOI: https://doi.org/10.1016/j.jdcr.2018.09.022

Howell R, Wright AM, Clements JN. Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date. Diabetes Metab Syndr Obes. 2019;12:505-12. DOI: https://doi.org/10.2147/DMSO.S174568

Aziz K, Shahbaz A, Zarghamravanbakhsh P, Ahmed SI, Sachmechi I. Generalized edema caused by albiglutide: a case report. Cureus. 2018;10(6):2801. DOI: https://doi.org/10.7759/cureus.2801

Micale SJ, Kane MP, Hogan E. Off-label use of liraglutide in the management of a pediatric patient with type 2 diabetes mellitus. Case Rep Pediatr. 2013;3:703925. DOI: https://doi.org/10.1155/2013/703925

Minervini G, Franco R, Marrapodi MM, Fiorillo L, Badnjević A, Cervino G, et al. Probiotics in the treatment of radiotherapy-induced oral mucositis: systematic review with meta-analysis. Pharmaceuticals (Basel). 2023;16(5):654. DOI: https://doi.org/10.3390/ph16050654

Rojekar MV, Sawant SD. A short review of pigmentation disorders in systemic diseases. Pigment Disord. 2015;2(4):2376-427.

Seo YG. Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes. J Obes Metab Syndr. 2021;30(1):12-9. DOI: https://doi.org/10.7570/jomes20059

Fortin SM, Chen J, Hayes MR. Hindbrain melanocortin 3/4 receptors modulate the food intake and body weight suppressive effects of the GLP-1 receptor agonist, liraglutide. Physiol Behav. 2020;20:112870. DOI: https://doi.org/10.1016/j.physbeh.2020.112870

Desai SR. Hyperpigmentation therapy: a review. J Clin Aesthet Dermatol. 2014;7(8):13-7.

Ohtsuki M, Morimoto H, Nakagawa H. Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: Review on safety and benefits. J Dermatol. 2018;45(8):936-42. DOI: https://doi.org/10.1111/1346-8138.14501

Sahni K, Gupta V, Khanna N. Hyperpigmentation in photo exposed patches of vitiligo following tacrolimus therapy. Indian Dermatol Online J. 2014;5(2):164-6. DOI: https://doi.org/10.4103/2229-5178.131090

Hassan S, Zhou XA. Drug-Induced Pigmentation. Treasure Island (FL): StatPearls Publishing. 2024. Available at: https://www.ncbi.nlm.nih.gov. Accessed on 18 December 2024.

Utz S, Suter VGA, Cazzaniga S, Borradori L, Feldmeyer L. Outcome and long-term treatment protocol for topical tacrolimus in oral lichen planus. J Eur Acad Dermatol Venereol. 2022;36(12):2459-65. DOI: https://doi.org/10.1111/jdv.18457

Resende JP, Chaves Md, Aarestrup FM, Aarestrup BV, Olate S, Netto HD. Oral lichen planus treated with tacrolimus 0.1%. Int J Clin Exp Med. 2013;6(10):917-21.

Krause W. Drug‐induced hyperpigmentation: a systematic review. J Deutschen Dermatologischen Gesellschaft. 2013;11(7):644-51. DOI: https://doi.org/10.1111/ddg.12042

Lynde CB, Kraft JN, Lynde CW. Topical treatments for melasma and post inflammatory hyperpigmentation. Skin Therapy Lett. 2006;11(9):1-6.

Salazar CE, Patil MK, Aihie O, Cruz N, Nambudiri VE. Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature. Archives of Dermatol Res. 2024;31(6):1-10. DOI: https://doi.org/10.1007/s00403-024-02969-3

George NM, Sangolli PM, Thulaseedharan A, Dominic S. Cutaneous Adverse Drug Reactions to Antidiabetic Medications and Medical Devices Used in Management of Diabetes Mellitus. Journal of Skin and Stem Cell. 2024;11(2):78. DOI: https://doi.org/10.5812/jssc-146625

Thongprasom K. A Review of the Effectiveness and side-effects of fluocinolone acetonide 0.1% in the treatment of oral mucosal diseases. Acta Stomatol Croat. 2017;51(3):240-7. DOI: https://doi.org/10.15644/asc51/3/8

Parrado C, Philips N, Gilaberte Y, Juarranz A, González S. Oral photoprotection: effective agents and potential candidates. Front Med (Lausanne). 2018;5:188. DOI: https://doi.org/10.3389/fmed.2018.00188